reported that an NRP1 deletion of CD8+ T cell substantially protected patients from tumor re-challenge and promoted response to anti-PD1 immunotherapy in head and neck squamous cell carcinoma (42, 46). The gene discussed is CD8A; the disease is neoplasm.